[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"degenerative-joint-disease-of-knee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:degenerative-joint-disease-of-knee":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100645287","intra-articular-adelmidrol-2hyaluronic-acid-1-with-or-without-mumpea-in-knee-pain-due-to-joint-degeneration-100645287",false,"NCT07680101","Intra-Articular Adelmidrol 2%\u002FHyaluronic Acid 1% With or Without m\u002FumPEA, in Knee Pain Due to Joint Degeneration.","Efficacy of Intra-articular Treatment With Adelmidrol 2% \u002F Hyaluronic Acid 1%, With or Without m\u002FumPEA, in Knee Pain Due to Joint Degeneration: a Bicentric, Prospective, Randomized Study.","Inclusion Criteria:\n\n* Age ≥ 40 years\n* Male or female\n* Diagnosis of unilateral or bilateral knee joint degeneration due to osteoarthritis or rheumatoid arthritis, Kellgren-Lawrence grade II-III\n* Duration of knee pain ≥ 6 months\n* Baseline WOMAC score ≥ 20\n* Drug therapy stabilized for at least 3 months in the case of patients with rheumatoid arthritis\n* Naïve to palmitoylethanolamide treatment\n* Signed informed consent\n\nExclusion Criteria:\n\n* Severe progressive systemic diseases\n* Contraindications to intra-articular knee injections\n* Intra-articular knee injections within 3 months prior to enrollment\n* Knee surgery within 6 months prior to enrollment\n* Systemic treatment with chondroprotectors within 1 month prior to enrollment\n* Systemic corticosteroid treatment within 1 month prior to enrollment\n* Chronic Non-Steroidal Anti-Inflammatory Drugs (NSAID) therapy\n* Pregnancy or breastfeeding\n* Known hypersensitivity to study treatments","ALL","40 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","Degenerative knee joint diseases are characterized by chronic pain, inflammation, and functional impairment. In these conditions, mast cell density in the synovial membrane is increased, resulting in an excessive release of biological mediators involved in key mechanisms of neuroinflammation and in hyaluronic acid depolymerisation. Adelmidrol acts as a preventive antioxidant due to its radical scavenging activity, thus protecting hyaluronic acid from oxidative degradation and reducing mast cell degranulation. Furthermore, a reduction in endogenous Palmitoylethanolamide (PEA) levels also contributes to joint neuroinflammation and disease progression; therefore, its exogenous supplementation may represent a valuable supportive strategy.\n\nThe objective of this clinical investigation is to compare the efficacy of intra-articular adelmidrol\u002Fhyaluronic acid treatment alone versus the same intra-articular treatment combined with oral micronized \u002Fultramicronized PEA in patients with knee joint degeneration due to osteoarthritis or rheumatoid arthritis.",[26,27],"Degenerative Joint Disease of Knee","Rheumatoid Arthritis",[29,30,31,32,33,34,35,36],"Neuroinflammation","Palmitoylethanolamide","Adelmidrol","Hyaluronic Acid","Intra-Articular Injection","Knee Pain","Arthritis, Rheumatoid","Osteoarthritis, Knee","NOT_YET_RECRUITING","2026-06-25",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":20},"2026-06",{"date":45,"type":20},"2027-06",{"name":47,"class":48},"Universita di Verona","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100613530","long-term-study-of-cartipro-for-knee-pain-due-to-osteoarthritis-or-cartilage-damage-100613530","NCT07267793","Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage","Long-term Efficacy and Safety of CartiPRO Injection to Alleviate Knee Pain in Patients With Osteoarthritis and\u002For Diverse Cartilage Defects: a Multicenter, Single-blind, Randomized, Non-inferiority, Sponsor Initiated Trial","Inclusion Criteria\n\n* Age 19 years and older\n* Diagnosed with unilateral or bilateral knee osteoarthritis according to American College of Rheumatology (ACR) criteria, with at least 3 of the following 6 features:\n\n  * Age ≥50 years\n  * Morning stiffness \\\u003C30 minutes\n  * Crepitus on active motion\n  * Bony tenderness\n  * Bony enlargement\n  * No palpable warmth\n* Radiographic evidence of Kellgren-Lawrence grade I, II, or III osteoarthritis within 6 months prior to screening or at screening visit\n* Weight-bearing pain Visual Analogue Scale (VAS) score ≥40 mm in at least one knee joint at screening\n* Able to walk without assistive devices (walkers or canes), OR if using a walking aid routinely for past 6 months, able to continue using the same device throughout the study\n* Able to understand and complete efficacy assessment questionnaires\n* Willing and able to provide written informed consent\n\nExclusion Criteria\n\n* Body Mass Index (BMI) ≥32 kg\u002Fm²\n* Chronic inflammatory joint disease (e.g., rheumatoid arthritis)\n* Inflammatory joint disease (e.g., septic arthritis)\n* Secondary knee osteoarthritis due to ochronosis, hemochromatosis, or systemic disease\n* Painful musculoskeletal conditions (e.g., Sudeck's atrophy, Paget's disease, herniated intervertebral disc)\n* Polyarticular disease with severe osteoarthritis in other joints (e.g., hip) that may affect knee pain evaluation\n* Radiographic evidence of definite loss of patellofemoral joint space\n* Moderate to severe joint effusion confirmed by positive patellar tap test or equivalent\n* History of myocardial infarction, congestive heart failure, other serious cardiac disease, or uncontrolled hypertension (≥140\u002F90 mmHg despite treatment with ≥3 antihypertensive agents)\n* History of autoimmune disease\n* Active infection requiring parenteral antibiotics\n* History of psychiatric disorder or epilepsy\n* Cancer diagnosis within 5 years prior to screening\n* Uncontrolled type 1 or type 2 diabetes mellitus (HbA1c \\>7%)\n* Surgical procedures (including arthroscopy) on target knee within 1 year (surgery on contralateral knee or hip may be exclusionary if it could affect target knee assessment)\n* Intra-articular corticosteroid injection into target knee within 12 weeks\n* Systemic corticosteroid use within 4 weeks (topical and inhaled corticosteroids permitted)\n* Surgery or radiation therapy to knee joint within 12 weeks, or not fully recovered from side effects\n* Immunosuppressive therapy (e.g., Cyclosporine A, Azathioprine) within 6 weeks\n* Intra-articular injections (e.g., hyaluronic acid) into knee joint within 6 months\n* Prohibited concomitant medications within 2 weeks (unless washout period is adequate)\n* Anticoagulants (e.g., warfarin, NOACs), antiplatelet agents (e.g., aspirin \\>100 mg\u002Fday, clopidogrel; low-dose aspirin ≤100 mg\u002Fday permitted), thrombolytic agents (e.g., urokinase, alteplase), or Vitamin E \\>1000 IU\u002Fday within 2 weeks (unless adequate washout)\n* Habitual use (≥3 months) of psychoactive drugs or narcotic analgesics that may affect pain perception\n* History of cell therapy or gene therapy to target joint\n* Planned cell therapy or gene therapy to target joint\n* Abnormal laboratory values at screening:\n* ALT, AST, BUN, or serum creatinine \\>2× upper limit of normal\n* Engaged in high-intensity aerobic or heavy anaerobic exercise that may affect the knee joint\n* Dermatological disease at injection site or site deemed unsuitable for injection\n* Ligament instability of Grade II or higher in target knee (Grade 0: none; Grade I: 0-5 mm; Grade II: 5-10 mm; Grade III: \\>10 mm)\n* Known hypersensitivity to investigational product or its components\n* Pregnant or breastfeeding women\n* Women or men of childbearing potential unwilling to use acceptable contraception during study (acceptable methods: intrauterine device, tubal ligation, sterilization surgery, condom or diaphragm with spermicide, natural family planning)\n* Participation in another clinical trial within 4 weeks\n* Cognitive impairment or dementia preventing informed consent\n* Any other condition that makes the subject unsuitable for study participation per investigator judgment","19 Years",{"count":59,"type":20},194,[23],"This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee osteoarthritis. The investigational device is administered intra-articularly, with a second injection given 24 weeks after the first dose. Primary and secondary endpoints include changes in pain scores (VAS), functional assessments (WOMAC, SF-36), and safety evaluations over a 36-week period.",[63,64,65,66,26],"Osteoarthritis","Knee Pain Arthritis","Cartilage Defects of the Knee","Knee Osteoarthritis","RECRUITING","2026-01-15",{"date":70,"type":41},"2026-01-20",{"date":72,"type":41},"2025-07-03",{"date":74,"type":20},"2026-10",{"name":76,"class":77},"DALIM TISSEN Co., Ltd.","INDUSTRY",5,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":78},"100289472","physica-system-total-knee-replacement-registry-study-100289472","NCT03048201","Physica System Total Knee Replacement Registry Study","Post-market Registry Study on the Physica System Total Knee Replacement","Inclusion Criteria:\n\n1. Males and females of any race requiring a total knee replacement and suitable for the use of one of the configurations of the Physica system\n2. Age\\> 22 (skeletally mature)\n3. Patients who are suffering from non-inflammatory degenerative joint disease (NIDJD):\n\n   including knee osteoarthritis, post-traumatic knee arthritis; or patients who are suffering from inflammatory arthritis; or patients that need correction of a functional deformity\n4. Suitable candidates for TKR who have undamaged and functional collateral ligaments\n5. Suitable candidates for TKR with Physica KR, CR, who have an undamaged and functional posterior cruciate ligament; or Physica LMC with or without a functioning posterior cruciate ligament or Physica PS with an absent or not-functioning posterior cruciate ligament and\u002For severe antero-posterior instability of the knee joint\n6. Patients who understand the conditions of the study and are willing and able to comply with the prescribed rehabilitation and to perform all scheduled follow-up visits\n7. Patients who have signed the Ethics Committee\u002FIRB approved study-specific Informed Consent Form prior to the surgery\n\nExclusion Criteria:\n\n1. Patients with severe instability of the knee joint secondary to the absence of collateral ligament integrity and\u002For function\n2. Patients with active or any suspected infection (on the affected knee or systemic)\n3. Previous partial knee replacement (unicompartimental, bicompartimental or patellofemoral joint replacement), patellectomy, high tibial osteotomy\n4. Patients with significant bone loss on femoral or tibial joint side\n5. Current treatment for malignant and\u002For life-threatening non-malignant disorders\n6. Patients with known incompatibility or allergy to the product materials, and\u002For metal hypersensitivity to implant materials\n7. Vascular insufficiency of lower limbs severe enough to interfere with the study evaluation\n8. Patients with bone stock compromised by disease, infection or prior implantation that cannot provide adequate support and\u002For fixation to the prosthesis\n9. Patients with systemic or metabolic disorders leading to progressive bone deterioration which may impair fixation and stability of the implant\n10. Any concomitant disease and dependence that might affect the performance of the implanted prosthesis\n11. Any clinically significant pathology based on clinical history that the Investigator feels may affect the study evaluation (e.g. primary osteoporosis with significant bone loss, haemophilic disease, septicaemia, persistent acute or chronic osteomyelitis)\n12. Patients who have significant neurological or musculoskeletal disorders or disease that may adversely affect gait and compromise functional recovery and evaluation\n13. Patients who have neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device\n14. Previous history of infection in the affected joint and\u002For other local\u002Fsystemic infection that may affect the prosthetic joint\n15. Any psychiatric illness that would prevent comprehension of the details and nature of the study\n16. Patients currently participating in any other surgical intervention studies or pain management studies\n17. Female patients who are pregnant, nursing, or planning a pregnancy","22 Years",{"count":88,"type":20},800,[23],"The primary objective of this study is to obtain long-term implant survivorship (out to 10 years) and to assess clinical, patient-reported outcome measures, and radiographic data for the commercially available Physica system. For ancillary arm, from baseline to 5-year follow-up.",[36,92,93,26,27,94],"Traumatic Arthritis","Avascular Necrosis","Deformity of Knee",[96,97,98,99,100,101,102],"Physica KR","Physica CR","Physica PS","Kinematic Retaining","Cruciate Retaining","Posterior Stabilized","Physica System","2023-03-17",{"date":105,"type":41},"2023-03-21",{"date":107,"type":41},"2017-03-24",{"date":109,"type":20},"2030-03",{"name":111,"class":77},"Limacorporate S.p.a"]